BRAF V600E mutation, TIMP-1 upregulation, and NF-κB activation: Closing the loop on the papillary thyroid cancer trilogy

Endocrine-Related Cancer

Volumn 18, Issue 6, 2011, Pages 669-685

  Bommarito, Alessandra ^a   Richiusa, Pierina ^a   Carissimi, Elvira ^a   Pizzolanti, Giuseppe ^a   Rodolico, Vito ^a   Zito, Giovanni ^a   Criscimanna, Angela ^a   Di Blasi, Francesco ^b   Pitrone, Maria ^a   Zerilli, Monica ^a   Amato, Marco C ^a   Spinelli, Gaetano ^b   Carina, Valeria ^a   Modica, Giuseppe ^a   Latteri, Adelfio ^a   Galluzzo, Aldo ^a   Giordano, Carla ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE V600E; CD63 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE B; SORAFENIB; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; GLUTAMIC ACID; TIMP1 PROTEIN, HUMAN; VALINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROID PAPILLARY CARCINOMA; UPREGULATION; AMINO ACID SUBSTITUTION; CELL TRANSFORMATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR; TUMOR CELL CULTURE;

ADULT; AMINO ACID SUBSTITUTION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR CELLS, CULTURED; UP-REGULATION; VALINE;

EID: 84855953821     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0076     Document Type: Article

References (55)

1. Baldini E, Toller M, Graziano FM, Russo FP, Pepe M, Biordi L, Marchioni E, Curcio F, Ulisse S, Ambesi-Impiombato FS et al. 2004 Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid 14 881-888. (doi:10.1089/thy.2004.14.881)
2. Baud V & Karin M 2009 Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls Nature Reviews. Drug Discovery 8 33-40. (doi:10.1038/nrd2781)
3. Berditchevski F & Odintsova E 1999 Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. Journal of Cell Biology 146 477-492. (doi:10.1083/jcb.146.2.477)
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI & Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 109-142. (doi:10.1089/thy.2006.16.109)
5. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States 1973-2002. Journal of the American Medical Association 295 2164-2167. (doi:10.1001/jama.295.18.2164)
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ & Bottomley W 2002 Mutations of BRAF gene in human cancer. Nature 417 949-954. (doi:10.1038/nature00766)
7. Deryugina EI & Quigley IP 2006 Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Reviews 25 9-34. (doi:10.1007/s10555-006-7886-9)
8. Dhomen N & Marais R 2007 New insight into BRAF mutations in cancer. Current Opinion in Genetics & Development 17 31-39. (doi:10.1016/j.gde.2006. 12.005)
9. Domingo-Domènech J, Pippa R, Tápia M, Gascón P, Bachs O & Bosch M 2008 Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Research and Treatment 112 53-62. (doi:10.1007/s10549-007-9837-8)
10. Fontaine JF, Mirebeau-Prunier D, Raharijaona M, Franc B, Triau S, Rodien P, Goëau-Brissonniére O, Karayan- Tapon L, Mello M, Houlgatte R et al. 2009 Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers. PLoS ONE 4 e7632. (doi:10.1371/journal.pone.0007632)
11. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F et al. 2008 BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocrine-Related Cancer 15 191-205. (doi:10.1677/ERC-07-0212)
12. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G & Vecchio G 1987 A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 328 170-172. (doi:10.1038/328170a0)
13. Garnett MJ & Marais R 2004 Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6 313-319. (doi:10.1016/j.ccr.2004.09.022)
14. Griffith OL, Melck A, Jones SJM & Wiseman SM 2006 Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. Journal of Clinical Oncology 24 5043-5505. (doi:10.1200/JCO.2006.06.7330)
15. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A & Stetler-Stevenson M 1998 In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. Journal of Clinical Investigation 102 2002-2010. (doi:10.1172/JCI2881)
16. Hawthorn L, Stein L, Varma R, Wiseman S, Loree T & Tan D 2004 TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head & Neck 26 1069-1083. (doi:10.1002/hed.20099)
17. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M & Tubeson DA 2003 Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research 63 5198-5202. (Pubitemid 37139827)
18. Hsu ChY, Ming-Tak D, Yang Ch F & Chiang H 2003 Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Modern Pathology 16 951-957. (doi:10.1097/01.MP.0000084631. 64279.BC)
19. Hundahl SA, Fleming ID, Fremgen AM & Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in U.S., 1985-1995. Cancer 83 2638-2648. (doi:10.1002/(SICI)1097-0142 (19981215)83:12〈2638::AID-CNCR31〉3.0.CO;2-1)
20. Ikenoue T, Hikiba Y, Kanai F, Aragaki J, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K et al. 2004 Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogenactivated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor B pathway and cellular transformation. Cancer Research 64 3428-3435. (doi:10.1158/0008-5472.CAN-03- 3591)
21. Jung KK, Liu XW, Chirco R, Fridman R & Kim HR 2006 Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO Journal 25 3934-3942. (doi:10.1038/sj.emboj.7601281)
22. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ et al. 2004 B-RAF is a therapeutic target in melanoma. Oncogene 23 6292-6298. (doi:10.1038/sj.onc. 1207785)
23. Karin M 2006 Nuclear factor-kB in cancer development and progression. Nature 441 431-436. (doi:10.1038/nature04870)
24. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457. (Pubitemid 36373628)
25. Kitchener P, Di Blasi F, Borrelli E & Piazza PV 2004 Differences between brain structures in nuclear translocation and DNA binding of the glucocorticoid receptor during stress and the circadian cycle. European Journal of Neuroscience 19 1837-1846. (doi:10.1111/j.1460-9568.2004.03267.x)
26. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P & Minafra S 2004 Zymographic detection and clinical correlation of MMP2 and MMP9 in breast cancer sera. British Journal of Cancer 90 1414-1421. (doi:10.1038/sj.bjc.6601725)
27. Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P & Hofman P 2010 Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. Current Medicinal Chemistry 17 1839-1850. (doi:10.2174/ 092986710791111189)
28. Leenhardt L, Grosclaude P & Cherie-Challine L 2004 Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee Thyroid 14 1056-1060. (doi:10.1089/thy.2004.14.1056)
29. Li G, Fridman R & Kim HR 1999 Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Research 59 6267-6275.
30. Liu D & Xing M 2008 Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kB pathways. Thyroid 18 853-864. (doi:10.1089/thy.2007.0357)
31. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R & Kim HR 2005 Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Research 65 898-906. (Pubitemid 40216449)
32. Liu D, Liu Z, Condouris S & Xing M 2007 BRAFV600E maintains proliferation, transformation and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 92 2264-2271. (doi:10.1210/jc.2006-1613)
33. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Böhm BO & Schmid RM 2001 Nuclear factor-kB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Research 61 64-67.
34. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, KruhofferMet al. 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 115 1068-1081. (doi:10.1172/JCI22758)
35. Mesa C, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF & Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFv600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extra cellular matrix remodeling. Cancer Research 66 6521-6529. (doi:10.1158/0008-5472.CAN-06-0739)
36. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni- Balafouta S & Mitsiades N 2006 Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. Journal of Clinical Endocrinology and Metabolism 91 3662-3666. (doi:10.1210/jc.2006-0055)
37. Okamura H, Yoshida K & Haneji T 2009 Negative regulation of TIMP1 is mediated by transcription factor TWIST1. International Journal of Oncology 35 181-186. (doi:10.3892/ijo-00000327)
38. Pacifico F & Leonardi A 2010 Role of NF-kappaB in thyroid cancer. Molecular and Cellular Endocrinology 321 29-35. (doi:10.1016/j.mce.2009.10.010)
39. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K et al. 2006 BRAFv600E promotes invasiveness of thyroid cancer cells through nuclear factor kB activation. Endocrinology 147 5699-5707. (doi:10.1210/en.2006-0400)
40. Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M et al. 2007 Fine-needle aspiration molecular analysis forthe diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 17 1109-1115. (doi:10.1089/thy.2007. 0008)
41. Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C & Seruca R 2008 BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF (V600E) but not KRAS mutations. Journal of Pathology 214 320-327. (doi:10.1002/path.2295)
42. Revest JM, Di Blasi F, Kitchener P, Rougé-Pont F, Desmedt A, Turiault M, Tronche F & Piazza PV 2005 The MAPK pathway and Egr-1 mediate stress-related behavioral effects of glucocorticoids. Nature Neuroscience 8 664-672 (Erratum in: Nature Neuroscience 8 835). (doi:10.1038/nn1441)
43. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A & Giordano C 2007 BRAF (V600E) mutation and p27(kip) expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases. Cancer 110 1218-1226. (doi:10.1002/cncr.22912)
44. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. New England Journal of Medicine 338 297-306. (doi:10.1056/NEJM199801293380506)
45. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC et al. 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 93 4331-4341. (doi:10.1210/jc.2008-1102)
46. Shinohara M, Chung YJ, Saji M & Ringel MD 2007 AKT in thyroid tumorigenesis and progression. Endocrinology 148 942-947. (doi:10.1210/en.2006- 0937)
47. Sounni NE & Noel A 2005 Membrane type-matrix metalloproteinases and tumor progression. Biochimie 87 329-342. (doi:10.1016/j.biochi.2004.07.012)
48. Stetler-Stevenson WG 2008 Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Science Signaling 1 re6. (doi:10.1126/scisignal.127re6)
49. Tuyt LM, Dokter WH, Birkenkamp K, Koopmans SB, Lummen C, Kruijer W & Vellenga E 1999 Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in Nf-kB-dependent IL-6 expression in human monocytes. Journal of Immunology 162 4893-4902. (Pubitemid 29314894)
50. Vale T, Ngo TT & White MA 2001 Lipsky Raf-induced transformation requires an interleukin 1 autocrine loop. Cancer Research 61 602-607. (Pubitemid 32128621)
51. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F et al. 1997 Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-kB p65 protein expression. Oncogene 15 1987-1994. (doi:10.1038/sj.onc.1201373)
52. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D et al. 2004 Mechanism of activation of the RAF-ER signaling pathway by oncogenic mutations of B-RAF. Cell 116 855-867. (doi:10.1016/S0092-8674(04)00215-6)
53. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases and clinical implications. Endocrine Reviews 28 742-762. (doi:10.1210/er.2007-0007)
54. Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, Werb Z & Clark OH 2006 Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocrine-Related Cancer 13 1173-1183. (doi:10.1677/erc.1.01226)
55. Zhang D, Qiu L, Jin X, Guo Z & Guo C 2009 Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. Molecular Cancer Research 7 1139-1149. (doi:10.1158/1541-7786.MCR-08-0410)